Print ISSN:-2394-2789

Online ISSN:-2394-2797

CODEN : IJPCN9

Article History

Received : 16-09-2021

Accepted : 17-09-2021



Article Metrics




Downlaod Files

   


Article Access statistics

Viewed: 542

PDF Downloaded: 386


Simultaneous analysis of eprosartan and hydrochlorothiazide in tablet formulation by High- Performance thin layer chromatography with ultraviolet absorption densitometry


Full Text PDF


Original Article

Author Details : Vrushali Tambe*, Vijaya Vichare, Anupa Wagh, Surekha Wavhal

Volume : 8, Issue : 3, Year : 2021

Article Page : 123-128

https://doi.org/10.18231/j.ijpca.2021.024



Suggest article by email

Get Permission

Abstract

A new, simple, accurate, and precise high-performance thin-layer chromatographic method has been established for simultaneous analysis of Eprosartan and Hydrochlorothiazide from a tablet formulation. Standard and sample solutions of Eprosartan and Hydrochlorothiazide were applied to precoated 250 ?m layer of silica gel G 60 F and the plates were developed with Chloroform: Acetonitrile: Glacial Acetic Acid (7:3:1,v/v/v) as mobile phase. Detection and evaluation of densitograms was performed densitometrically at 254 nm. The linear range was 200-700 ng/band with the retention factors of Eprosartan and Hydrochlorothiazide were 0.26± 0.02 and 0.44±0.02, respectively. The method was validated and successfully used for analysis of the drugs in tablets.


Keywords: Eprosartan, HPTLC, Hydrochlorothiazide, Tablets, Validation



How to cite : Tambe V, Vichare V, Wagh A, Wavhal S, Simultaneous analysis of eprosartan and hydrochlorothiazide in tablet formulation by High- Performance thin layer chromatography with ultraviolet absorption densitometry. Int J Pharm Chem Anal 2021;8(3):123-128


This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.